



In re Application of:)
BIRGER SÖRENSEN) Examiner: Stucker, Jeffrey J.
Application No.: 10/659,324) Group Art Unit: 1648
Filed: September 11, 2003)
For: METHOD OF PRODUCING)
AN HIV-1 IMMUNE RESPONSE)

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

DECLARATION UNDER 37 C.F.R. 1.132
OF DR. INGEBJØRG BAKSAAS

Sir:

I, Ingebjørg Baksaas, having a residence address of Grensegata 65, NO 3715
Skien, Norway, hereby declare and state as follows:

1. I hold a Ph.D. in Pharmacology and Epidemiology, awarded me in 1980 by
University of Oslo, Department of Medicine.
2. I am currently the Chief Executive Officer of Mericon, AS, of Skien,
Norway, a company that designs and oversees clinical studies of proposed new pharmaceuticals.
3. I have coordinated and monitored a phase II clinical study of the
effectiveness of four different synthetic peptides for stimulating the immune system of a human
to produce an HIV-1 immune response. The peptides all correspond to conserved domains of the

HIV-1 p24 capsid protein. They are the peptides that are identified in the above-captioned patent application as SEQ ID NO: 3, 6, 11, and 18. Attached hereto, as Exhibits A and B, are two reports that discuss the results of that study.

4. I declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed by me to be true; and further, that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

Ingebjørg Baksaas

Dated this 25 day of July, 2005

